Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K Inhibitors

Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K Inhibitors

On-Demand Webcast
Faculty

Carla Casulo, MD
University of Rochester
Rochester, New York

Bruce D. Cheson, MD, FACP, FAAAS, FASCO
Lombardi Comprehensive Cancer Center
Georgetown University Hospital
Washington, District of Columbia

Richard I. Fisher, MD
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Thomas M. Habermann, MD
Mayo Clinic
Rochester, Minnesota

Peter Martin, MD
Weill Cornell Medicine
New York, New York

Ari M. Melnick, MD
Weill Cornell Medicine
New York, New York

Target Audience

This activity is intended for hematologists/oncologists, PAs, NPs, nurses, and pharmacists who specialize in hematology, as well as other HCPs who care for patients with hematologic malignancies.

Overview

Advances in understanding the pathophysiologic mechanisms of hematologic malignancies in recent years have led to the advent of new and highly effective medications for the treatment of the many subtypes of heterogenic and often deadly diseases, including follicular lymphoma (FL). FL is the most common form of indolent non-Hodgkin lymphoma (iNHL), accounting for an estimated 20% of the nearly 75,000 patients diagnosed with NHL in the United States each year. Treatment challenges are common with FL. FL patients with a high tumor burden or advanced-stage disease traditionally receive first-line chemoimmunotherapy (CIT), and the majority of cases initially respond well to such treatment. However, most patients will eventually develop R/R disease that no longer responds to the initial therapeutic regimen, leaving these patients with limited treatment options. In recent years, PI3K inhibitors have emerged as potent treatment options in R/R FL. In light of this rapidly changing treatment landscape, hematologists and oncologists must overcome a number of clinical practice gaps that may interfere with providing optimal patient care.

This webcast aims to update clinicians on the latest clinical trial data surrounding new therapies and combinations of therapies for the treatment of FL; optimal sequencing based on current data; within-class differences among new targeted therapies; and the latest research on mechanisms of side effects and strategies to allow patients to remain on treatment.

Objectives

Upon successful completion of this educational activity, participants should be better able to:

  1. Describe the physiologic functions and tissue distributions of the various class I PI3K isoforms that are current therapeutic targets for the treatment of FL
  2. Outline the most recent clinical trial data reported for targeted medications approved for the treatment of R/R FL
  3. Identify patients with R/R or high-risk FL in clinical practice who may benefit from PI3K therapy

Release Date: December 31, 2019

Expiration Date: December 31, 2020

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Support

Supported by an educational grant from: Verastem Oncology.

Accreditation

 In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

PHYSICIANS

NACCME designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHYSICIAN ASSISTANTS

NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 credit(s).

PAs should only claim credit commensurate with the extent of their participation.

CNE

This continuing nursing education activity awards 1.5 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.5 contact hours.

CPE

This knowledge-based activity (JA0006201-9999-20-046-H01-P) is approved for 1.5 contact hours (0.15 CEUs) of continuing pharmacy education.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises Carla Casulo, MD, Bruce D. Cheson, MD, FACP, FAAAS, FASCO, Richard I. Fisher, MD, Thomas M. Habermann, MD, Peter Martin, MD, Ari M. Melnick, MD; and Chris Bolwell, Lara Gray, and Griselda Zuccarino-Catania Imedex.

 

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME and Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant financial relationships that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME and Imedex to initiate a mechanism to resolve any conflicts. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Carla Casulo, MD, reports that she has received grant or research support from Celgene and Verastem; and has received other financial support from Gilead.

Bruce D. Cheson, MD, FACP, FAAAS, FASCO, reports that he is a consultant for Abbvie, AstraZeneca, Celgene, Karyopharm, Morphosys, Pharmacyclics, Roche-Genentech, and TG Therapeutics; and has received grant support from Abbvie, AstraZeneca, Gilead, Pharmacyclics, Roche-Genentech, TG Therapeutics, and Trillium. 

Richard L. Fisher, MD, reports that he is a consultant for AstraZeneca and Celgene.

Thomas M. Habermann, MD, reports that he has nothing to disclose in relation to this activity.

Peter Martin, MD, reports that he is a consultant for Acerta, Celgene, I-MAB, Janssen, Karyopharm, Sandoz, and Teneobio; and has received grant or research support from Karyopharm.

Ari M. Melnick, MD, reports that he has is a consultant for Epizyme and Constellation Pharmaceuticals; has received grant or research support from Janssen Biotech; and is a stockholder of KDAC Therapeutics.

Chris Bolwell discloses that he holds shares of stock of GlaxoSmithKline.

Griselda Zuccarino-Catania disclosed that her spouse is employed by Janssen Pharmaceuticals, Inc.

Lara Gray disclosed no relevant financial relationships with any commercial interests.

UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME or Imedex.

Privacy Policy

NACCME and Imedex protect the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME, Imedex and our joint providers will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME and Imedex maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2019 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.